• Mashup Score: 1
    Benralizumab treatment of severe asthma in pregnancy: A case series - 7 month(s) ago

    Asthma exacerbations, oral corticosteroid use, and increased asthma severity are associated with adverse perinatal outcomes.1 Asthma biologics have transformed the management of severe asthma (SA), but the clinical trials that served as the basis for regulatory approvals for the biologics excluded pregnant women, and data on their safety and efficacy during pregnancy are limited. Here, we present a case series on the use of benralizumab, an IL-5 receptor antagonist, in pregnant women with SA. We obtained informed consent from all patients.

    Source: www.jaci-inpractice.org
    Categories: Allergy-Immunology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JACIInPractice
      JACIInPractice

      In Current Issue! #Benralizumab #treatment of #severe #asthma in #pregnancy: A #case #series https://t.co/6ZKpjO3M3k https://t.co/BkXlCDm5fT

  • Mashup Score: 0
    The burden of ischemic heart disease and the epidemiologic transition in the Eastern Mediterranean Region: 1990–2019 - 8 month(s) ago

    It has been estimated that in the next decade, IHD prevalence, DALYs and deaths will increase more significantly in EMR than in any other region of the world. This study aims to provide a comprehensive description of the trends in the burden of ischemic heart disease (IHD) across the countries of the Eastern Mediterranean Region (EMR) from 1990 to 2019. Data on IHD prevalence, disability-adjusted life years (DALYs), mortality, DALYs attributable to risk factors, healthcare access and quality index (HAQ), and universal health coverage (UHC) were extracted from the Global Burden of Disease (GBD) database for EMR countries. The data were stratified based on the social demographic index (SDI). Information on cardiac rehabilitation was obtained from publications by the International Council of Cardiovascular Prevention and Rehabilitation (ICCPR), and additional country-specific data were obtained through advanced search methods. Age standardization was performed using the direct method, app

    Source: journals.plos.org
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of NHLBI_Translate
      NHLBI_Translate

      .@PLOSone: Trends in the burden of ischemic #heart disease and the epidemiologic transition in the Eastern #Mediterranean region: 1990–2019. #deaths #disability #prevalence #risks #SDOH. Crucial need for #prevention and #treatment. @IHME #GBD #ImpSci Read: https://t.co/lVSTIuIEaG https://t.co/z2hMw2GPTd

  • Mashup Score: 3
    Controversies in Allergy: Are Biologic Treatment Responses in Severe Asthma the Same in Adults and Children? - 8 month(s) ago

    The availability of biologic agents for patients with severe asthma has increased dramatically over the last several decades. The absence of direct head-to-head comparative data and relative lack of biomarkers to predict response can make it difficult to choose the right biologic medication for a given patient. Selecting a biologic agent for the pediatric population presents further challenges due to more limited approved biologic agents and fewer clinical trials in children. In addition, the outcome data that are currently available suggest that treatment responses for a given biologic may be different between adult and pediatric patients.

    Source: www.jaci-inpractice.org
    Categories: Allergy-Immunology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JACIInPractice
      JACIInPractice

      In Press! #Controversies in #Allergy: Are #Biologic #Treatment #Responses in #Severe #Asthma the Same in #Adults and #Children? https://t.co/zLhlpkLQgn https://t.co/MeP7VrK23L

  • Mashup Score: 0
    Izervay receives FDA approval for geographic atrophy - 9 month(s) ago

    The FDA approved Izervay, a complement C5 inhibitor, for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Astellas Pharma.

    Source: www.healio.com
    Categories: General Medicine News, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of GoHealio
      GoHealio

      #FDA approves Izervay for #geographicatrophy, slowing disease #progression by up to 35% in the first year of #treatment. #ophthalmology #MedTwitter #healthnews https://t.co/mEwxDmiEEn

  • Mashup Score: 3
    Idiopathic pulmonary fibrosis in the United States: time to diagnosis and treatment - BMC Pulmonary Medicine - 9 month(s) ago

    Objective Create a timeline of diagnosis and treatment for IPF in the US. Design, setting, and participants A retrospective analysis was performed in collaboration with the OptumLabs Data Warehouse using an administrative claims database of Medicare Fee for Service beneficiaries. Adults 50 and over with IPF were included (2014 to 2019). Exposure To focus on IPF, the following diagnoses were excluded: post-inflammatory fibrosis, hypersensitivity pneumonitis, rheumatoid arthritis, sarcoidosis, scleroderma, and connective tissue disease. Main outcomes and measures Data were collected from periods prior, during, and following initial clinical diagnosis of IPF. This included prior respiratory diagnoses, number of respiratory-related hospitalizations, anti-fibrotic and oxygen use, and survival. Results A total of 44,891 with IPF were identified. The most common diagnoses prior to diagnosis of IPF were upper respiratory infections (47%), acute bronchitis (13%), other respiratory disease (10%)

    Source: bmcpulmmed.biomedcentral.com
    Categories: Latest Headlines, Pulmonology
    Tweet Tweets with this article
    • Profile photo of ATS_BSHSR
      ATS_BSHSR

      #IPF in the United States: #time to #diagnosis and #treatment https://t.co/1ipUGQEDrp https://t.co/ggrFtjdRR7

Load More